AB2 Bio has made an option and licencing agreement with Nippon Shinyaku, granting the latter the option to obtain exclusive rights to commercialise Tadekinig alfa in the US. This therapy treats a ...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in ...

Tadekinig alfa is designed to bind and block IL-18. Credit: TheCorgi/Shutterstock. AB2 Bio has made an option and licencing agreement with Nippon Shinyaku, granting the latter the option to obtain ...

Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...

Inflammatory diseases specialist AB2 Bio Ltd. has signed a potential $686 million U.S. commercialization deal for its interleukin-18 neutralizing drug tadekinig. The agreement with Japanese pharma ...

Privately-held Swiss biotech AB2 Bio has entered into an option and licensing agreement with Japan’s Nippon Shinyaku (TYO: 4519), which it describes as having extensive experience in marketing rare ...

AB2 Bio Ltd., developing therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18, has entered into an option and licensing agreement with Nippon ...